Cargando…
Deciphering the Cardiovascular Potential of Human CD34(+) Stem Cells
Ex vivo monitored human CD34(+) stem cells (SCs) injected into myocardium scar tissue have shown real benefits for the recovery of patients with myocardial infarctions. They have been used previously in clinical trials with hopeful results and are expected to be promising for cardiac regenerative me...
Autores principales: | Aries, Anne, Zanetti, Céline, Hénon, Philippe, Drénou, Bernard, Lahlil, Rachid |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253329/ https://www.ncbi.nlm.nih.gov/pubmed/37298503 http://dx.doi.org/10.3390/ijms24119551 |
Ejemplares similares
-
Differential Expression of the Tetraspanin CD9 in Normal and Leukemic Stem Cells
por: Lahlil, Rachid, et al.
Publicado: (2021) -
Development of a potency assay for CD34(+) cell-based therapy
por: Aries, Anne, et al.
Publicado: (2023) -
Industrialized GMP Production of CD34(+) Cells (ProtheraCytes®) at Clinical Scale for Treatment of Ischemic Cardiac Diseases Is Feasible and Safe
por: Hénon, Philippe, et al.
Publicado: (2022) -
VSELs Maintain their Pluripotency and Competence to Differentiate after Enhanced Ex Vivo Expansion
por: Lahlil, Rachid, et al.
Publicado: (2018) -
Design and Validation of an Automated Process for the Expansion of Peripheral Blood‐Derived CD34(+) Cells for Clinical Use After Myocardial Infarction
por: Saucourt, Claire, et al.
Publicado: (2019)